Journal article

Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial

Nicolas Senn, Patricia Rarau, Danielle I Stanisic, Leanne Robinson, Celine Barnadas, Doris Manong, Mary Salib, Jonah Iga, Nandao Tarongka, Serej Ley, Anna Rosanas-Urgell, John J Aponte, Peter A Zimmerman, James G Beeson, Louis Schofield, Peter Siba, Stephen J Rogerson, John C Reeder, Ivo Mueller



Awarded by Bill & Melinda Gates Foundation

Funding Acknowledgements

This work was supported by a grant to the PNG Institute of Medical Research from the Bill & Melinda Gates Foundation's Global Health Program (Grand ID# 34678). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.We are very grateful to the study participants, the populations, the members of community health associations, and the staff of the health centers of Mugil, Alexishafen, Kunjingini, and Kaugia for their cooperation throughout the study. Special thanks to the PNG IPTi field teams, in particular Joe Nale, Bridget Barber, the study nurses, and the community reporters for their dedicated work in the field; the microscopy, molecular parasitology, and immunology teams for accurate malaria diagnosis and sample preparation; Samson Akunaii, Carol Davy, Carol Taime, Lisa Kandi, Gilda Nongi, and the IPTi project management team for providing administrative and financial services support to the project; Rose Sabub for database management; Tom Smith (Swiss Tropical and Public Health Institute) for the production of the random allocation lists; and Tim Davis and team at the University of Western Australia for measurement of SP, AS, and AQ drug levels. Our special thanks go also to the members of the Data Safety Monitoring Board (John Vince, Trevor Duke, and Margaret Hellard), to the clinical monitors (Cornelia Bevilacqua and Leo Nascher), and to the PNG Department of Health and PNG Pediatric Society for their support and advice. Last but not least, we thank Kinapharma and IPCA, who manufactured the trial drugs.